Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29587568 | 1.00 | IDO1 (0.47) | IDO1GPR119HRH3HDAC1HDAC2 | |
| SCHEMBL1690860 | 0.93 | IDO1 (0.47) | IDO1GPR119HRH3HDAC1HDAC2 | |
| SCHEMBL13069176 | 0.90 | IDO1 (0.47) | IDO1GPR119HRH3HDAC1HDAC2 | |
| SCHEMBL23928864 | 0.89 | HRH3 (0.38) | IDO1GPR119HRH3HDAC1HDAC2 | |
| SCHEMBL2346324 | 0.88 | IDO1 (0.47) | IDO1GPR119HRH3HDAC1HDAC2 | |
| SCHEMBL12491393 | 0.88 | IDO1 (0.57) | IDO1GPR119HRH3 | |
| SCHEMBL31236088 | 0.88 | IDO1 (0.57) | IDO1GPR119HRH3 | |
| SCHEMBL307381 | 0.85 | KCNH2 (0.49) | IDO1GPR119 | |
| SCHEMBL308722 | 0.85 | KCNH2 (0.49) | IDO1GPR119 | |
| SCHEMBL743496 | 0.85 | IDO1 (0.45) | IDO1GPR119HRH3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022120048-A1 | HDAC INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-06-09 | — | — | WO | disclosed |
| EP-2414366-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | Novartis AG (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2012-01-12 | — | — | US | disclosed |
| WO-2010112520-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2010-10-07 | — | — | WO | disclosed |
| US-7547708-B2 | N-sulfamoyl-N′-benzopyranpiperidine compounds and uses thereof | SOLVAY PHARMACEUTICALS, INC. (DE) | 2009-06-16 | — | — | US | disclosed |
| US-20070117823-A1 | N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof | SOLVAY PHARMACEUTICALSS GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
| WO-2007054580-A1 | N-SULFAMOYL-N’-BENZOPYRANPIPERIDINES AS INHBITORS OF CARBONIC ANHYDRASES | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | IDO1 3801/4885GPR119 184/4885HRH3 4825/4885 |
| US-20070117823-A1 | N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof | SCN2A, NAPEPLD, SCN5A | IDO1 2491/4885GPR119 15/4885HRH3 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.